Trimethylamine N-oxide Effects of a Pomegranate Supplement Simultaneously With Carnitine (TESSA)

NCT ID: NCT06518343

Last Updated: 2025-06-15

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 39 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-08-12
• Study Completion Date: 2027-05-31

Brief Summary

Trimethylamine N-oxide (TMAO) is produced in some individuals whose diets include meat, fish, and dairy.These foods are rich in L-carnitine. L-carnitine is metabolised by the liver and gut microorganisms (bacteria) into TMAO. In the TESSA study, investigators will explore whether pomegranate extract can lower the production of TMAO in healthy men and women. This reduction in TMAO production has been associated with decreasing a person's risk of heart disease.

Detailed Description

The TESSA study is a 18 day randomised, double-blind, placebo-controlled two-arm crossover pilot study conducted at the NIHR (National Institute for Health and Care Research) Norfolk Clinical Research Facility (CRF) in the Quadram Institute in Norwich. Investigators are seeking men and women over the age of 18 years who habitually consume meat, fish, and/or eggs and are TMAO producers to determine whether pomegranate extract affects L-carnitine metabolism compared to a matched placebo. This study is conducted in two phases. The first phase involves two study visits where investigators will identify and invite TMAO producing individuals to continue to the second phase of this study. Moreover, investigators will ask the participant to complete a food frequency questionnaire. The second phase involves two intervention periods which are separated by a 10 day washout. Each intervention period begins with a run-in followed by three study visits. Investigators will precisely quantify the absorption (blood plasma concentrations over time, pharmacokinetic study) and metabolism of L-carnitine and its products of metabolism which includes TMAO. Additionally, investigators will examine pomegranate metabolism and excretion with timed urine collections and stool samples.

Participants will consume three L-carnitine capsules at the first visit during the first phase. In the second phase, participants will consume L-carnitine capsules with the intervention capsules (pomegranate extract or placebo) for the first intervention period then after the washout period, participants will crossover and consume L-carnitine capsules with the other intervention capsules for the second intervention period. For each intervention period, three L-carnitine capsules with four intervention capsules at the first visit following the run-in. During the second phase starting at the run-in period participants will be asked to follow a standardized, controlled diet which will be low in choline, L-carnitine, and ellagitannins.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: TRIPLE

Study Groups

Pomegranate extract

1.5 grams L-carnitine (Carnipure®) + 1.6 grams pomegranate extract (Dermogranate®) in hydroxypropyl methylcellulose (HPMC) capsules

Group Type: EXPERIMENTAL

L-carnitine + Pomegranate extract

Intervention Type: DIETARY_SUPPLEMENT

Participants will consume 1.5 grams L-carnitine with 1.6 grams pomegranate extract at one visit during one intervention period

Microcrystalline cellulose

1.5 grams L-carnitine (Carnipure®) + 1.5 grams microcrystalline cellulose (MCC, Redwells Health) in hydroxypropyl methylcellulose (HPMC) capsules

Group Type: PLACEBO_COMPARATOR

L-carnitine + Microcrystalline cellulose

Intervention Type: DIETARY_SUPPLEMENT

Participants will consume 1.5 grams L-carnitine with 1.5 grams microcrystalline cellulose at one visit during one intervention period

Interventions

L-carnitine + Pomegranate extract

Participants will consume 1.5 grams L-carnitine with 1.6 grams pomegranate extract at one visit during one intervention period

Intervention Type: DIETARY_SUPPLEMENT

L-carnitine + Microcrystalline cellulose

Participants will consume 1.5 grams L-carnitine with 1.5 grams microcrystalline cellulose at one visit during one intervention period

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• Individuals who regularly eat meat (4 portions of meat per week for at least 2 months prior to enrolment in the study).
• Aged 18 and older.
• Body Mass Index (BMI) between 18.5 - 30 kg/m2.
• Living within 40 miles from the Norwich Research Park.

• TMAO producer (plasma TMAO increase of >5 µM and >50% after L-carnitine ingestion.

Exclusion Criteria

• Consume an entirely vegan, vegetarian, or pescatarian diet within the last two months.
• Do not have access to a freezer to store some provided meals and ice packs.
• Have a known allergy to the tablets, capsules (i.e., pomegranate), or standardised meals such as wheat, eggs, milk, nuts, and soybeans.
• Have difficulty swallowing, a swallowing disorder, or are unable to swallow four capsules (the size of a peanut) and three L carnitine tablets consecutively within a time span of ten minutes.
• Have bowel movements less than five times a week.
• Are a current smoker (or stopped smoking for less than 3 months).
• Consume more than 14 units of alcohol per week (for example, a pint of beer or a 175 mL glass of wine each count as two units).
• Are pregnant or breastfeeding.
• Have anaemia or any conditions or medications that may hinder clotting. This will be assessed on a case-by-case basis.
• Have high or low blood pressure (i.e., ≤90/60 or ≥160/100 mmHg).
• Have a medical condition or take medications that may affect the primary outcome of this study, such as but not limited to diabetes, liver disease, hypo/hyperthyroidism, or fish odour syndrome. This will be assessed on a case-by-case basis.
• Have had gastrointestinal disease or surgical procedures that may affect the primary outcome of this study. This will be assessed on a case-by-case basis.
• Have known or a history of kidney disease, this will be determined by the medical advisor using blood urea nitrogen and creatinine levels in the participant's blood.
• Regularly use bowel cleansing techniques like colonic irrigation or laxatives.
• Had an infection or received antibiotics within a month prior to this study.
• Regularly take dietary supplements that may affect the primary outcome measure of this study, such as fish oil or L carnitine supplements.
• Are currently undergoing active treatment for cancer or heart disease.
• Participated in another dietary intervention study within the last four months.
• Have donated a large quantity of blood within the last 16 weeks. Registered donors should abstain from blood donations for the duration of the study.
• Are a person related to or living with a member of the study team.
• Are unable to give written or verbal informed consent.
• Participant is unable to provide GP (General Practitioner) contact details.
• Have symptoms of Coronavirus infection (COVID-19), been asked to self-isolate, or have been diagnosed with COVID-19 in the last 14 days.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Norfolk and Norwich University Hospitals NHS Foundation Trust

OTHER

Sponsor Role: collaborator

Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)

OTHER

Sponsor Role: collaborator

Quadram Institute Bioscience

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Paul Kroon, PhD

Role: PRINCIPAL_INVESTIGATOR

Quadram Institute Bioscience

Locations

Quadram Institute

Norwich, Norfolk, United Kingdom

Countries

United Kingdom

Other Identifiers

336410

Identifier Type: REGISTRY

Identifier Source: secondary_id

QIB01/2024

Identifier Type: -

Identifier Source: org_study_id